Comparison of EMLA cream with piroxicam gel for reducing pain associated with needling of arteriovenous fistula during haemodialysis

Not Applicable

Recruiting

• Conditions: end stage renal disease; Haemodialysis; Renal and Urogenital - Kidney disease

• Registration Number: ACTRN12622000943741
• Lead Sponsor: Samia Shaheen

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2022-07-04
• Last Update Posted: 9 August 2022

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 16

Inclusion Criteria

Patients with end stage renal disease, undergoing haemodialysis with a native upper limb arteriovenous fistula

Exclusion Criteria

Use of tunnelled dialysis catheters or arteriovenous grafts for haemodialysis
Unwilling patients
Known Hypersensitivity to any ingredient of the agents
Patients with ulcer/ wound at fistula site
Neuropathies causing loss of pain sensation
Atopic dermatitis
Co-morbidity resulting in participants' inability to validating the visual analog scale, e.g.,altered sensorium, psychiatric patients

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Intensity of pain during arteriovenous fistula needling, assesses by a numerical rating scale ranging from 0 (no pain). to 10 (maximum possible pain) [At the time of arteriovenous fistula needling]

Secondary Outcome Measures

Name	Time	Method
one[None]